1196875-90-7Relevant academic research and scientific papers
QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS
-
Page/Page column 151-153, (2020/04/25)
The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.
QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY
-
Paragraph 0216; 0217, (2016/02/29)
Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.
Glucokinase Activators
-
Page/Page column 109-111, (2009/12/05)
Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
INDOLES AS 5-HT6 MODULATORS
-
Page/Page column 119-120, (2008/06/13)
The present invention relates to novel compounds of formula (I) wherein m, n, R0, R1, R2, R3 and R4 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for t
